Indivior plc
http://indivior.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Indivior plc
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.
Novo Pumps Up Heart Failure Prospects With Cardior Purchase
The Danish drugmaker is spending some of its semaglutide cash on a mid-stage RNA-based heart failure therapy developed by the German biotech.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.
Novo Nordisk Calls On Two Flagship Firms For Early Science In Metabolic Health
Derived from a 2022 collaboration between the two, Novo Nordisk will partner with Flagship-backed Omega in obesity and Cellarity in NASH. Both programs are in very early stages at present.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Indivior Inc.
- Indivior UK Limited
- Reckitt Benckiser Pharmaceuticals Inc. (RBP)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice